Elosulfase Alfa For Morquio A Syndrome Equipment
1 equipment items found
-
Manufactured by BioMarinbased in USA
Vimizim (elosulfase alfa) is the first approved enzyme replacement therapy designed to address the underlying cause of Morquio A syndrome, or mucopolysaccharidosis IVA (MPS IVA) — a deficiency in the enzyme N-acetylgalactosamine-6 sulfatase (GALNS). VIMIZIM works at a cellular level to help with deficient enzyme ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you